Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial. - Wikidata - wikimedia - TriplyDB

Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.

Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.

http://www.wikidata.org/entity/Q37672827

about

Natural Medicines for Psychotic Disorders: A Systematic Review.A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials.

P2860

Q49363880-94D1FF7A-13D9-49BE-8CB4-B9A2B1CD6542 Q50109827-93CDE382-87D4-462E-A53B-61BEBFC9CDD5

P2860

Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.

http://www.wikidata.org/entity/Q37672827

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@en

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@nl

type

label

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@en

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@nl

prefLabel

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@en

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@nl

P1433

Q37672827-BB4EE816-B5E7-4AD2-A465-01CAEF820514

P1476

Q37672827-776CAD80-2065-4C7D-AB0E-2642AF8AA517

P2093

Q37672827-0C0443AB-7958-4627-B5F9-E86CC086EB05

Q37672827-1BEEA0F3-9A9B-44DB-B0BE-F54D73D4E579

Q37672827-7097DC87-532F-4561-A049-E254BF55035F

Q37672827-75AEA590-E7AF-4D18-9CE9-046C8569D805

Q37672827-9E7FB064-BF21-4C67-8EFC-C5ECB6392859

Q37672827-9EC14DAC-5ECF-44FB-8627-B595D9D370F6

Q37672827-B13E3DB3-DD1D-4B75-80FF-97745C249593

Q37672827-BEAF311A-9E91-4EE1-8972-40BC75372810

P2860

Q37672827-034583EF-E6CF-49EB-B716-D911C12FE161

Q37672827-0FAC3115-968F-49B7-9908-B6F624608CC8

Q37672827-14D1CC5F-53F4-4EAE-8511-6F3748EB2B9A

Q37672827-3025D88D-1975-417F-BD47-5995CDB5FF41

Q37672827-37DBFB4D-692C-4712-8C35-99DC4EFCEE66

Q37672827-395E1A96-BB7C-4970-81CF-4A67FC837BB1

Q37672827-44A2FCCB-BFC9-45EE-8FD2-6C3D9E0E4E10

Q37672827-50A39D30-DAAD-4019-A681-3690F74727A6

Q37672827-56F614BF-2056-46DF-8F6E-E791D86CB326

Q37672827-59DF1030-06EE-429E-8C05-E4E6FD08216E

P304

Q37672827-8AFC505E-03C9-4B6E-B638-FD6AC3B023D6

P31

Q37672827-930C7F5D-8898-4A55-BB41-F247E1563298

P356

Q37672827-4F3B2C14-8DD2-4356-82F4-F72DFA21AD28

P433

Q37672827-A69BF4E5-AA51-4D9A-A50E-47FB44DB069A

P478

Q37672827-3692DB5E-687E-4300-AE9A-0161F07B9DCF

P577

Q37672827-5BB73E9C-8934-4411-9BCC-76171A76CC48

P5875

Q37672827-E5A6A73B-9F47-4325-B5E3-B82354A4C645

P698

Q37672827-F875844C-A0E6-4548-AE74-DB697F97E6BE

P921

Q37672827-5B262F3E-0B86-4558-82A2-DEF15019FE74

Q37672827-B3912418-B61C-4303-ACF6-6655019E8543

Q37672827-B45A5821-7AE9-4F02-A77D-1FE3171EF58A

P932

Q37672827-4DD8EE83-8570-4080-BF5F-EBBDEDFC3653

P356

J.CURTHERES.2008.04.008

P1433

Current Therapeutic Research

P1476

Effectiveness and tolerability ...... ebo-controlled clinical trial.

@en

P2093

Gao-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Hong-Bing Mei

http://www.w3.org/2001/XMLSchema#string

Hui-Lin Wang

http://www.w3.org/2001/XMLSchema#string

Ming-Hua Yang

http://www.w3.org/2001/XMLSchema#string

Ren-Yun Chen

http://www.w3.org/2001/XMLSchema#string

Xiao-Ping Wang

http://www.w3.org/2001/XMLSchema#string

Yun-Xiang Huo

http://www.w3.org/2001/XMLSchema#string

Zhen-Hua Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year followup.

Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia.

The NIMH-MATRICS consensus statement on negative symptoms.

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review.

The current clinical practice of herbal medicine in psychiatry in mainland China: a review of literature.

Training patients with schizophrenia with the community re-entry module: a controlled study.

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Correlates of cognitive deficits in first episode schizophrenia.

P304

104-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CURTHERES.2008.04.008

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

222890520

http://www.w3.org/2001/XMLSchema#string

P698

24692790

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3969969

http://www.w3.org/2001/XMLSchema#string